Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Share Capital

v3.24.1
Share Capital
12 Months Ended
Dec. 31, 2023
Share Capital [Abstract]  
SHARE CAPITAL

NOTE 8 - SHARE CAPITAL

 

A. Ordinary shares

 

  1) Rights of the Company’s ordinary shares

 

Each ordinary share is entitled to one vote. The holder of the ordinary shares is also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends.

 

On January 31, 2018 the Company’s ADSs commenced trading on the Nasdaq Capital Market, under the symbol CLGN. On May 25, 2021, The Company's ordinary shares were approved for trading on the Nasdaq Global Market, and began trading at the open of market on June 4, 2021. At such time, the Company's ADSs were mandatorily cancelled and exchanged for ordinary shares at a one-for-one ratio. 

 

  2) Changes in share capital:

 

  a)

During January-April 2021, one of the Company’s shareholder exercised 992,149 warrants into 992,149 ADS in return of $3,969.

 

In 2021, one of the U.S investors exercised 450,000 warrants into 450,000 ordinary shares in return of $1,800.

 

In 2022, three U.S investors exercised 425,000 warrants into 425,000 ordinary shares in return of $1,700.

 

In 2023, Mr. Sagy exercised 186,000 warrants into 186,000 ordinary shares in return of $744.

 

  b)

On February 17, 2021, the Company completed a registered direct offering providing for the sale and issuance of an aggregate of 2,000,000 ADSs at a purchase price of $17.50 per ADS, for aggregate gross proceeds of $35,000. The total issuance costs accumulated to $3,200.

 

On the same date, one of the Company’s investors transferred the Company an amount of $1,000 by way of an equity investment, and the Company issued to the investor 250,000 ADSs representing 250,000 ordinary shares and a warrant to purchase up to 250,000 ADSs representing 250,000 ordinary shares.

 

The following table summarizes information about warrants outstanding and exercisable as of December 2023:

 

    Year ended December 31, 2023      
Issuance date   warrants outstanding     Exercise
price per warrant
    warrants outstanding and exercisable     Contractual term
February 17, 2021     250,000     $ 4.00       250,000     February 17, 2024
                             
B. Share-based compensation:

 

  1)

Option plan

 

Under the Company’s Share Ownership and Option Plan (2010), or the 2010 Plan, employees, directors and consultants of the Company may be granted options, each exercisable into one ordinary share of the Company of NIS 1.50 par value.

 

  2) Options grants

 

  a. Option granted to employees and directors  

 

In the years ended December 31, 2023, 2022 and 2021, the Company granted options as follows (amounts presented reflect the number of shares underlying options):

 

    Year ended December 31, 2023  
    Award
amount
    Exercise
price range
    Vesting
period
  Expiration  
Employees     158,000     $ 5.65-7.5     4 years   10 years  

 

    Year ended December 31, 2022  
    Award
amount
    Exercise
price range
    Vesting
period
  Expiration  
Employees     529,000     $ 5.33-9.22     4 years   10 years  
Directors     217,000     $ 9.22     4 years   10 years  

 

 

 

  Year ended December 31, 2021  
    Award
amount
    Exercise
price range
    Vesting
period
  Expiration  
Employees     96,500     $ 12.78-20.7     4 years   10 years  
Directors     23,000     $ 15.2     4 years   10 years  

 

The fair value of options granted on the date of grant was computed using the Black-Scholes model. The underlying data used for computing the fair value of the options are as follows:  

 

    Year ended December 31,  
    2023     2022     2021  
Value of one ordinary share   $ 5.73-7.5     $ 5.03-9.22     $ 11.9-20.37  
Dividend yield     0 %     0 %     0 %
Expected volatility     70.27-74.1 %     67.95-72.27 %     65.36-66.49 %
Risk-free interest rate     3.62-4.33 %     0.39-3.03 %     0.64-1.37 %
Expected term     6.11 years       6.11 years       6.11 years  

  

The fair value of options granted during 2023, 2022 and 2021 was $747, 3,970 and $1,094 respectively.

 

The total unrecognized compensation cost of options on December 31, 2023 is $1,342, which is expected to be recognized over a weighted average period of 1.64 year.

 

Modification of share-based compensation

 

On August 23, 2023, the Company’s board of directors approved the repricing of the exercise price of outstanding options to purchase 969,886 ordinary shares, previously granted to employees and directors, to a price of $6.39 per share, out of which the repricing of 583,979 options granted to the Company’s directors and the Chief Executive Officer, were subject to the approval of the general meeting of the shareholders, which approval was obtained on October 10, 2023. There was no change in the number of shares subject to each option, vesting or other terms of the options. 

 

The total incremental fair value of these options amounted to $579 and was determined based on the Black-Scholes pricing options model using the following assumptions: risk free interest rate of 4.33%-4.74%, expected volatility of 72.1% - 77%, expected term of 3.4-4.71 years and dividend yield of 0%. For the year ended December 31, 2023, the Company recorded expenses totaling $523 associated with the repricing. The remaining incremental fair value will be recognized over the remaining vesting period and until May 2026.

 

A summary of options data for the years ended December 31, 2023, 2022 and 2021, is as follows:

 

    Year ended December 31,  
    2023     2022     2021  
Weighted-average grant date fair value of options granted, per option   $ 4.73     $ 5.32     $ 9.16  
Total intrinsic value of the options exercised   $ 271     $ 221     $ 869  
Total fair value of options vested   $ 4,380     $ 2,802     $ 3,356  

 

A summary of the activity in options granted to employees and directors for the year ended December 31, 2023 is as follows:

 

    2023  
    Number of
options
    Weighted
average
exercise
price*
    weighted average remaining contractual term (in years)     aggregate intrinsic value*  
Options outstanding at the beginning of the year     1,868,749     $ 6.02       6.81     $ 4,620  
Granted     158,000       7.05      
-
     
-
 
Exercised     (76,441 )     4.52      
-
     
-
 
Expired     (83,156 )     9.79      
-
     
-
 
Forfeited     (121,272 )     8.81      
-
     
-
 
Options outstanding at the end of the year     1,745,880     $ 5.8       5.91     $ 1,165  
Options exercisable at the end of the year     1,151,015     $ 5.49       4.6     $ 1,062  

 

* After repricing- see Note 8(B)(2)(a).

 

  b. Option granted to non-employees

 

A summary of the activity in options granted to non-employees for the year ended December 31, 2023 is as follows:

 

    2023  
    Number of
options
    Weighted
average
exercise
price
    weighted average remaining contractual term (in years)     aggregate intrinsic value  
Options outstanding at the beginning of the year     15,416     $ 16.04       1.79     $ 23  
Exercised     (3,750 )     5.07                  
Options outstanding at the end of the year     11,666     $ 16.78       1.36     $ 2  
Options exercisable at the end of the year     6,329     $ 10.00       1.34     $ 2  

 

The following tables summarize information concerning outstanding and exercisable options as of December 31, 2023:

 

December 31, 2023  
Options outstanding     Options exercisable  
Exercise prices *     Number of
options
outstanding
at end of year
    Weighted
average
remaining
contractual Life
    Number of
options
exercisable
at end of year
    Weighted
average
remaining
contractual life
 
$ 24.81       6,666       1.38       1,329       1.38  
  6.07       5,000       1.33       5,000       1.33  
  10.08       2,625       0.17       2,625       0.17  
  5.07       149,500       2.08       149,500       2.08  
  4.02       352,464       1.29       352,464       1.29  
  9.22       3,905       0.11       3,905       0.11  
  5.33       111,000       8.92       27,750       8.92  
  7.5       103,000       9.25      
-
     
-
 
  6.5       33,500       9.65      
-
     
-
 
  5.65       20,000       9.2      
-
     
-
 
$ 6.39       969,886       7.33       614,771       6.97  
          1,757,546               1,157,344          

 

* In U.S. dollars per Ordinary Share.

 

  c. The following table illustrates the effect of share-based compensation on the statements of operations:

 

    Year ended December 31  
    2023     2022     2021  
Cost of revenues   $
-
    $ 22     $ 78  
Research and development expenses     714       565       525  
General, administrative and marketing expenses     1,223       1,587       1,017  
    $ 1,937     $ 2,174     $ 1,620